Emerging therapeutic agents for lung cancer

Bhagirathbhai Dholaria, William Hammond, Amanda Shreders, Yanyan Lou

Research output: Contribution to journalReview article

53 Citations (Scopus)

Abstract

Lung cancer continues to be the most common cause of cancer-related mortality worldwide. Recent advances in molecular diagnostics and immunotherapeutics have propelled the rapid development of novel treatment agents across all cancer subtypes, including lung cancer. Additionally, more pharmaceutical therapies for lung cancer have been approved by the US Food and Drug Administration in the last 5 years than in previous two decades. These drugs have ushered in a new era of lung cancer managements that have promising efficacy and safety and also provide treatment opportunities to patients who otherwise would have no conventional chemotherapy available. In this review, we summarize recent advances in lung cancer therapeutics with a specific focus on first in-human or early-phase I/II clinical trials. These drugs either offer better alternatives to drugs in their class or are a completely new class of drugs with novel mechanisms of action. We have divided our discussion into targeted agents, immunotherapies, and antibody drug conjugates for small cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). We briefly review the emerging agents and ongoing clinical studies. We have attempted to provide the most current review on emerging therapeutic agents on horizon for lung cancer.

Original languageEnglish (US)
Article number138
JournalJournal of Hematology and Oncology
Volume9
Issue number1
DOIs
StatePublished - Dec 9 2016

Fingerprint

Lung Neoplasms
Pharmaceutical Preparations
Therapeutics
Phase II Clinical Trials
Clinical Trials, Phase I
Molecular Pathology
Small Cell Lung Carcinoma
United States Food and Drug Administration
Non-Small Cell Lung Carcinoma
Immunotherapy
Neoplasms
Safety
Drug Therapy
Mortality
Antibodies

Keywords

  • Immunotherapy
  • Lung cancer
  • Phase I/II clinical trial
  • Targeted agents

ASJC Scopus subject areas

  • Hematology
  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

Emerging therapeutic agents for lung cancer. / Dholaria, Bhagirathbhai; Hammond, William; Shreders, Amanda; Lou, Yanyan.

In: Journal of Hematology and Oncology, Vol. 9, No. 1, 138, 09.12.2016.

Research output: Contribution to journalReview article

Dholaria, Bhagirathbhai ; Hammond, William ; Shreders, Amanda ; Lou, Yanyan. / Emerging therapeutic agents for lung cancer. In: Journal of Hematology and Oncology. 2016 ; Vol. 9, No. 1.
@article{1aa5fe49b38b41b09babcd05c21eb27e,
title = "Emerging therapeutic agents for lung cancer",
abstract = "Lung cancer continues to be the most common cause of cancer-related mortality worldwide. Recent advances in molecular diagnostics and immunotherapeutics have propelled the rapid development of novel treatment agents across all cancer subtypes, including lung cancer. Additionally, more pharmaceutical therapies for lung cancer have been approved by the US Food and Drug Administration in the last 5 years than in previous two decades. These drugs have ushered in a new era of lung cancer managements that have promising efficacy and safety and also provide treatment opportunities to patients who otherwise would have no conventional chemotherapy available. In this review, we summarize recent advances in lung cancer therapeutics with a specific focus on first in-human or early-phase I/II clinical trials. These drugs either offer better alternatives to drugs in their class or are a completely new class of drugs with novel mechanisms of action. We have divided our discussion into targeted agents, immunotherapies, and antibody drug conjugates for small cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). We briefly review the emerging agents and ongoing clinical studies. We have attempted to provide the most current review on emerging therapeutic agents on horizon for lung cancer.",
keywords = "Immunotherapy, Lung cancer, Phase I/II clinical trial, Targeted agents",
author = "Bhagirathbhai Dholaria and William Hammond and Amanda Shreders and Yanyan Lou",
year = "2016",
month = "12",
day = "9",
doi = "10.1186/s13045-016-0365-z",
language = "English (US)",
volume = "9",
journal = "Journal of Hematology and Oncology",
issn = "1756-8722",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Emerging therapeutic agents for lung cancer

AU - Dholaria, Bhagirathbhai

AU - Hammond, William

AU - Shreders, Amanda

AU - Lou, Yanyan

PY - 2016/12/9

Y1 - 2016/12/9

N2 - Lung cancer continues to be the most common cause of cancer-related mortality worldwide. Recent advances in molecular diagnostics and immunotherapeutics have propelled the rapid development of novel treatment agents across all cancer subtypes, including lung cancer. Additionally, more pharmaceutical therapies for lung cancer have been approved by the US Food and Drug Administration in the last 5 years than in previous two decades. These drugs have ushered in a new era of lung cancer managements that have promising efficacy and safety and also provide treatment opportunities to patients who otherwise would have no conventional chemotherapy available. In this review, we summarize recent advances in lung cancer therapeutics with a specific focus on first in-human or early-phase I/II clinical trials. These drugs either offer better alternatives to drugs in their class or are a completely new class of drugs with novel mechanisms of action. We have divided our discussion into targeted agents, immunotherapies, and antibody drug conjugates for small cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). We briefly review the emerging agents and ongoing clinical studies. We have attempted to provide the most current review on emerging therapeutic agents on horizon for lung cancer.

AB - Lung cancer continues to be the most common cause of cancer-related mortality worldwide. Recent advances in molecular diagnostics and immunotherapeutics have propelled the rapid development of novel treatment agents across all cancer subtypes, including lung cancer. Additionally, more pharmaceutical therapies for lung cancer have been approved by the US Food and Drug Administration in the last 5 years than in previous two decades. These drugs have ushered in a new era of lung cancer managements that have promising efficacy and safety and also provide treatment opportunities to patients who otherwise would have no conventional chemotherapy available. In this review, we summarize recent advances in lung cancer therapeutics with a specific focus on first in-human or early-phase I/II clinical trials. These drugs either offer better alternatives to drugs in their class or are a completely new class of drugs with novel mechanisms of action. We have divided our discussion into targeted agents, immunotherapies, and antibody drug conjugates for small cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). We briefly review the emerging agents and ongoing clinical studies. We have attempted to provide the most current review on emerging therapeutic agents on horizon for lung cancer.

KW - Immunotherapy

KW - Lung cancer

KW - Phase I/II clinical trial

KW - Targeted agents

UR - http://www.scopus.com/inward/record.url?scp=85004140713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85004140713&partnerID=8YFLogxK

U2 - 10.1186/s13045-016-0365-z

DO - 10.1186/s13045-016-0365-z

M3 - Review article

C2 - 27938382

AN - SCOPUS:85004140713

VL - 9

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

SN - 1756-8722

IS - 1

M1 - 138

ER -